Zimmer Biomet Holdings, Inc. (ZBH) Stock: Price, Forecast & Analyst Target
Zimmer Biomet Holdings, Inc. (ZBH) — MoonshotScore 79/100 (Strong band), calculated Nov 18, 2026. Price $101.47 (-1.79%), as of the Nov 19, 2026 trading session; market cap $19.2B. Expected results Feb 9, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Zimmer Biomet Holdings, Inc. · ZBH · NYSE · Healthcare · Medical - Devices
Research dated 2026-09-12: Zimmer Biomet sells orthopedic reconstruction systems led by knee and hip products, alongside sports medicine, trauma, extremities, spine, dental and related surgical offerings across major global regions. The unresolved tension is whether spending on the United States commercial organization can translate product demand into durable growth without prolonging margin pressure.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Zimmer Biomet Holdings (ZBH)
StrongWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality and durable growth, though the balance sheet is only middling; the market is already moving on it. Business Quality: Elite; Financial Safety: Okay; Valuation: Fair; Growth Durability: Compounding; Momentum: Surging.
- EPS beat 0 of the last 4 reports
- expected results Feb 9, 2027
- Altman Z 2.40 · Piotroski F 7
Helping: business quality, an attractive price, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 81 | Exceptional | |
| 80 | Exceptional | |
| 80 | Exceptional | |
| 80 | Exceptional | |
| 79 | Strong | |
| 79 | Strong |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $101.47 | |
| Change on the day | -1.79% | |
| 52-week range | $79.12–$112.55 | |
| Market capitalisation | $19.2B | — |
| Price / earnings (trailing) | 25.72 | |
| Shares traded on the day | 1.85M | |
| Beta (volatility vs the S&P 500) | 0.47 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for Zimmer Biomet Holdings (ZBH): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 17, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Zimmer Biomet Holdings (ZBH), and what does it report?
Short answer · as of
Zimmer Biomet is an orthopedic reconstruction specialist rather than a general hospital-equipment vendor.
Research dated 2026-09-12.
It designs, manufactures and markets products used in joint reconstruction and related surgical fields, so revenue reflects demand for implants and surgical products across procedures and markets.
Reporting uses a geographic lens across the Americas, Europe, the Middle East, Africa and Asia Pacific, while the product view separates knees, hips and S E T. Knees form the largest disclosed product pool, making joint reconstruction more important to the revenue mix than the broad medical-device label suggests.
What do the latest results show for Zimmer Biomet Holdings (ZBH)?
Research dated 2026-09-12.
The latest quarter delivered higher revenue and gross profit than the preceding period and the comparable prior period. Operating profit, net income and diluted earnings per share retreated sequentially but improved against the comparable period, showing that growth has not yet produced a smooth profit progression.
Estimate comparisons use an adjusted earnings series that sits above reported diluted earnings per share, so an earnings beat and the statutory profit trend answer different questions. Management raised its organic constant-currency revenue outlook and expects foreign exchange to help reported growth, while forecasting further operating-margin pressure from investment in the United States commercial organization. Selling and administrative expense rose sequentially and against the comparable period, consistent with that explanation without proving causation.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $2.00B | $231M | $1.16 (diluted) |
| Q4 FY2025 | $2.24B | $139M | — |
| Q1 FY2026 | $2.09B | $238M | $1.22 (diluted) |
| Q2 FY2026 | $2.18B | $198M | $1.03 (diluted) |
What are the financial strengths and risks for Zimmer Biomet Holdings (ZBH)?
Short answer
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-12.
Operating cash flow remained positive throughout the reported series and strengthened in the latest quarter against the preceding and comparable periods. Liquidity ratios remain above parity, free cash flow is meaningful relative to market value, and the regular dividend has continued at an unchanged recent rate.
The balance sheet is nevertheless far from a net-cash position. Debt vastly exceeds cash and short-term investments, while cash ended below its level at the start of the reported window despite considerable fluctuations between periods. Rising annual revenue accompanied falling net income in the latest year, so sustained cash conversion matters more than revenue growth alone when assessing the leverage burden.
What should you watch next at Zimmer Biomet Holdings (ZBH)?
Short answer · as of
The next earnings report is expected on Feb 9, 2027.
Research dated 2026-09-12.
At the scheduled earnings release, separate organic constant-currency growth from the expected foreign-exchange benefit. Operating margin and selling expense deserve particular attention because management has guided to a further sequential margin decline while attributing pressure to commercial investment.
Adjusted earnings have met or exceeded estimates throughout the displayed history, while revenue recorded an isolated miss. Continued beats would carry less information than evidence that reported operating profit and operating cash flow are strengthening alongside sales. Longer-range consensus assumes rising revenue and earnings per share, making progress in knees, hips and S E T—and either a cash rebuild or debt reduction—the more useful confirmation points.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
Checked against the records this page reads, on the dates shown above.
How does Zimmer Biomet Holdings compare with its peers?
Short answer
Zimmer Biomet Holdings's score ranks 10th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12.
Zimmer Biomet belongs beside diversified orthopedic reconstruction businesses, not broad device makers centered on diagnostics or monitoring. Its disclosed mix is anchored by knees, followed by hips and S E T, while geographic reach spans major markets across the Americas, Europe, the Middle East, Africa and Asia Pacific.
That combination concentrates the economics around musculoskeletal procedures despite broad geographic coverage. Gross profitability is substantial, but current commercial spending is pressing operating margin, so comparison with similar businesses should emphasize conversion of gross profit into operating profit and cash after selling and research expense rather than sales growth in isolation.
| Company | Price | Market value | Score |
|---|---|---|---|
| $577.34 Nov 18, 2026 | $24.6B | 97 5-pillar Nov 18, 2026 | |
| $70.53 Nov 18, 2026 | $9.34B | 94 5-pillar Nov 18, 2026 | |
| $80.19 Nov 19, 2026 | $29.9B | 93 5-pillar Nov 18, 2026 | |
| $105.23 Nov 18, 2026 | $60.5B | 93 5-pillar Nov 18, 2026 | |
| $320.00 Nov 19, 2026 | $12.6B | 92 5-pillar Nov 18, 2026 | |
| $259.57 Nov 18, 2026 | $25.2B | 87 5-pillar Nov 18, 2026 | |
| $139.98 Nov 18, 2026 | $9.71B | 85 5-pillar Nov 18, 2026 | |
| $29.83 Nov 19, 2026 | $12.5B | 84 5-pillar Nov 18, 2026 | |
| $163.96 Nov 18, 2026 | $11.6B | 83 5-pillar Nov 18, 2026 | |
| Zimmer Biomet Holdings (ZBH) — this page | $101.47 | $19.2B | 79 |
| $29.27 Nov 19, 2026 | $28.6B | 78 5-pillar Nov 18, 2026 | |
| $370.17 Nov 18, 2026 | $9.95B | 77 5-pillar Nov 18, 2026 | |
| $258.99 Nov 19, 2026 | $28.5B | 74 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $93.00 – $140.00
- Consensus target
- $112.00
- Median target
- $112.00
Consensus record · Captured .
Measured against a quoted price of $101.47 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Oct 1, 2026
- Transactions
- 28
- Identified insiders
- 12
- Purchases
- 0
- Sales
- 4
- Other transactions
- 24
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held ZBH in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported ZBH in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Zimmer Biomet Holdings (ZBH)?
Common Questions About ZBH (Healthcare)
Research dated 2026-09-12; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
Why are knees so important to Zimmer Biomet?
Knees are Zimmer Biomet’s largest disclosed product revenue category, ahead of hips and S E T. Their scale means changes in knee-product demand can materially shape companywide growth even though the portfolio extends across many orthopedic and surgical fields.
Why can Zimmer Biomet revenue rise while reported earnings fall?
Revenue and gross profit can advance while selling expense absorbs more of the gain. The latest sequential comparison shows exactly that pattern, and management links expected operating-margin pressure to investment in the United States commercial organization.
Why do Zimmer Biomet’s adjusted and diluted earnings differ?
The estimate history compares an adjusted earnings measure, while the income statement presents diluted earnings under the reported accounting basis. An estimate beat therefore does not mean reported net income or diluted earnings improved sequentially.
Why does Zimmer Biomet report by geography when knees lead product revenue?
The geographic segments show where Zimmer Biomet operates, while the product categories show what generates sales. Reading them together reveals a globally distributed business whose disclosed product mix remains concentrated in joint reconstruction.
What is the ZBH stock price today?
The last price recorded for Zimmer Biomet Holdings, Inc. (ZBH), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the ZBH price target?
The analyst consensus price target for Zimmer Biomet Holdings, Inc. (ZBH), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 24 figures on this page — 1 from SEC filings and earnings calls, 19 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-12), by section of the research
ETFs that hold ZBH
Funds in our ETF coverage that list ZBH among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| LGHT ETF | 4.23% |